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Abstract
In order to elucidate factors that determine substrate specificity and activity of mammalian molybdo-flavoproteins we
performed site directed mutagenesis of mouse aldehyde oxidase 3 (mAOX3). The sequence alignment of different aldehyde
oxidase (AOX) isoforms identified variations in the active site of mAOX3 in comparison to other AOX proteins and xanthine
oxidoreductases (XOR). Based on the structural alignment of mAOX3 and bovine XOR, differences in amino acid residues
involved in substrate binding in XORs in comparison to AOXs were identified. We exchanged several residues in the active
site to the ones found in other AOX homologues in mouse or to residues present in bovine XOR in order to examine their
influence on substrate selectivity and catalytic activity. Additionally we analyzed the influence of the [2Fe-2S] domains of
mAOX3 on its kinetic properties and cofactor saturation. We applied UV-VIS and EPR monitored redox-titrations to
determine the redox potentials of wild type mAOX3 and mAOX3 variants containing the iron-sulfur centers of mAOX1. In
addition, a combination of molecular docking and molecular dynamic simulations (MD) was used to investigate factors that
modulate the substrate specificity and activity of wild type and AOX variants. The successful conversion of an AOX enzyme
to an XOR enzyme was achieved exchanging eight residues in the active site of mAOX3. It was observed that the absence of
the K889H exchange substantially decreased the activity of the enzyme towards all substrates analyzed, revealing that this
residue has an important role in catalysis.
Citation: Mahro M, Bra´s NF, Cerqueira NMFSA, Teutloff C, Coelho C, et al. (2013) Identification of Crucial Amino Acids in Mouse Aldehyde Oxidase 3 That
Determine Substrate Specificity. PLoS ONE 8(12): e82285. doi:10.1371/journal.pone.0082285
Editor: Annalisa Pastore, National Institute for Medical Research, Medical Research Council, London, United Kingdom
Received September 20, 2013; Accepted November 1, 2013; Published December 16, 2013
Copyright:  2013 Mahro et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Cluster of Excellence ‘‘Unifying Concepts in Catalysis’’ (to C.T. and S.L.) coordinated by the Technische Universita¨t Berlin
and funded by the Deutsche Forschungsgemeinschaft. The exchange of researchers among laboratories involved in the work was funded by the DAAD-GRICES
program (to MJ Roma˜o and S Leimku¨hler). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sleim@uni-potsdam.de
Introduction
Aldehyde oxidases (AOX, EC 1.2.3.1) are complex molybdo-
flavoenzymes (MFEs) containing two distinct [2Fe-2S] centers,
FAD and the molybdenum cofactor (Moco) as catalytically acting
units. The enzymes are homodimers in eukaryotes and belong to
the family of xanthine oxidases (XO) of molybdoenzymes. Despite
their high sequence identity of about 50%, AOXs and xanthine
oxidoreductases (XOR) use different sets of substrates. Both
enzymes display a broad substrate specificity acting on activated
carbon atoms in -C = N- and -C(-H) = O bonds [1,2]. While
XORs prefer low substituted purines as substrates, AOXs prefer
higher substituted aromatic compounds. MFEs in general are
characterized by a homodimeric butterfly-shaped structure of
about 300 kDa in size. Three subdomains of each subunit
containing three different cofactors characterize the structure of
mammalian MFEs, a 20 kDa N-terminal [2Fe-2S] domain, a
40 kDa central FAD-containing domain and an 85 kDa C-
terminal molybdenum cofactor (Moco) domain [3,4]. The Moco
of eukaryotic AOX and XOR is further modified by an equatorial
sulfur ligand coordinating the molybdenum atom, which is
essential for their catalytic function [5,6]. The oxidation of
substrates starts with a base-catalyzed nucleophilic addition of Mo-
OH to the reducing substrate and concerted hydride transfer from
the reducing substrate to the Mo = S moiety. The molybdenum is
reduced from +VI to +IV in this reaction. The covalent
intermediate is hydrolyzed by water releasing the oxidized product
[7]. The electrons are transferred via the two [2Fe-2S] centers
(FeSI nearest to the Moco and FeSII nearest to the FAD [8]) to the
FAD cofactor. In AOX enzymes molecular oxygen is used as
terminal electron acceptor, producing mainly H2O2. In XORs,
the oxidase form (XO) uses O2 as electron acceptor, while the
dehydrogenase form (XDH) prefers NAD+ as electron acceptor
[9]. The inability of the oxidase form to reduce NAD+ has been
assigned to structural changes upon oxidation or proteolytic
cleavage that block the NAD+ binding site by sterical hindrance
[10]. Alongside, the oxidase form shows a,170 mV more positive
reduction potential of the FADHu/FADH2 couple in comparison
to the dehydrogenase form, which preferentially yields the two
electron reduced form of FAD being able to react with molecular
oxygen [11]. So far, rabbit liver AOX is the only eukaryotic AOX
for which redox potentials were determined [12]. The order of
redox potentials of the FAD/FADHu couple and the FADHu/
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FADH2 couple of rabbit liver AOX was shown to be comparable
to the one identified in XOs [9].
While XORs have a defined role in the catabolism of purines,
the physiological role of AOXs is not known and only at the
beginning to be understood [3]. Recent results imply a role in
lipid-homeostasis and UV-light response [13–15] as well as
pheromone reception [16]. While XORs are encoded by a single
species-specific gene, for AOX enzymes different isoforms were
identified in different species. Rodents and marsupials contain the
largest number of Aox functional genes: Aox1, Aox3, Aox4, and
Aox3l1 [17,18]. These genes arose from a series of gene duplication
events from a common ancestor and are clustered on a short
region of mouse chromosome 1 and rat chromosome 9. All of the
products of the mammalian Aox genes have high amino acid
sequence similarity and are expressed in a tissue-specific manner
in different organisms [3,19]. It is believed that the various AOX
isoforms recognize distinct substrates and carry out different
physiological tasks. The tissue distribution of mouse AOX3
(mAOX3) is superimposable to that of mAOX1, and the two
enzymes are synthesized predominantly in liver, lung, and testis
[20]. The expression of mAOX4 is limited to the Harderian gland,
esophagus and skin, whereas mAOX3L1 expression is restricted to
the nasal mucosa [21]. mAOX4 was shown to metabolize
retinaldehyde into retinoic acid and plays a role in skin
homeostasis [13]. Due to low-abundance and overlapping tissue-
distribution purification of one AOX-isoform is difficult without
any cross-contaminations of other AOX-isoforms. Therefore, little
is known about substrate specificities and kinetic properties of the
different AOX isoforms. Independently from the physiological role
of AOXs, inter-species and inter-individual differences in AOX
promoted drug metabolism has evolved to a challenging issue in
drug development [22]. Understanding the mechanisms deter-
mining the different substrate specificities and the factors
determining the reactivity of AOX is one of the main goals in
this field. Recent recombinant expression systems in hand enabled
to meet the increasing interest in understanding the molecular
bases of AOXs substrate specificity.
In this study we use the existing recombinant expression system
for mAOX3 in Escherichia coli to study the basis of catalytic activity
and substrate selectivity of mAOX3 in comparison to other AOX
homologues from mouse and bovine XOR (bXOR). We
exchanged amino acids in the first and second coordination
sphere of the mAOX3 active site to amino acids found in XOR
and other AOX isoforms. The variant mAOX3-F776K/A807E/
D878L/L881S/Y885R/P1015T/Y1019L showed drastically de-
creased activity towards all substrates tested. Additional introduc-
tion of K889H substitution rescued AOX activity and resulted in a
XOR-like activity with hypoxanthine as substrate. Additionally,
we introduced the iron-sulfur center domains of mAOX1 in
mAOX3. Changes in activity as well as iron-sulfur center I (FeSI)
formal potentials were observed.
Results and Discussion
Site-directed mutagenesis of mAOX3
In order to determine the role of different amino acids in the
active sites of AOXs, the variants mAOX3-F1014I, mAOX3-
F1014V, mAOX3-P1015A and mAOX3-P1015G were generat-
ed. Additionally, we performed ‘‘whole domain’’ exchanges to
study differences in the intramolecular electron transfer. We
exchanged the [2Fe-2S]-containing domains of mAOX3 to the
ones present on mAOX1 to study their influence on electron
transfer and catalytic activity of mAOX3. The variant mAOX3-
FeSII-mAOX1 exhibits the amino acids M1 – P76 from mAOX1
instead of M1 – P80 of mAOX3. In mAOX3-FeSI-mAOX1, A87
– Q214 of mAOX3 is exchanged by T83 – Q213 of mAOX1 and
mAOX3-FeSII-FeSI-mAOX1 possesses M1 – Q213 from
mAOX1 replacing M1 – Q214 from mAOX3. In order to study
amino acids, which determine the substrate specificity of XOR
enzymes in comparison to AOX enzymes, we performed
numerous exchanges of amino acids in the first and second
coordination sphere of the active site of mAOX1 to the ones
present in bXOR. The variant named mAOX3-‘‘active site1’’
contains the seven amino acid exchanges F776K/A807E/D878L/
L881S/Y885R/P1015T/Y1019L in mAOX3, which represent
highly conserved amino acids in XOR enzymes (Fig. 1). The
mAOX3-‘‘active site1’’-K889H variant contains in addition the
K889H exchange, since the lysine was shown to be involved in
substrate binding in AOX enzymes [23]. All variants named
‘‘gating loop’’ contain the amino acid exchanges K889H/
S1011G/V1012I/G1013S/K1016V/Y1020N, which are in the
vicinity of the active site. These amino acids are part of a
hydrogen-bond network in the second coordination sphere of
XORs, which is mainly build by R880 (Y885 in mAOX3), G1006-
S1008 (S1011-G1013 in mAOX3) and N1015 (Y1020 in
mAOX3). All 11 mAOX3 variants were expressed and purified
from 28 – 112 liter cultures as described previously for mAOX3
wild type [24]. Figure 2 shows wild type mAOX3 and the purified
variants separated on an 8% native polyacrylamide gel. All
variants were purified as dimers with a comparable yield of 0.5 –
1.2 mg/L of culture and a purity of approx. 95%. As shown in
Table 1, all variants showed a comparable molybdopterin (MPT)
saturation of 62624% – 139637% relative to mAOX3 wild type.
The iron content was found to be similar with a saturation ranging
from 49615% to 75624%. The ratio of absorbance at 444 nm
and 550 nm was around 3.2 for all variants, showing an equal
ratio of FAD to the 2x[2Fe-2S] clusters. Molybdenum saturation
ranged from 4568% to 101616%. The molybdenum to MPT
ratio in all variants was found to be comparable to the mAOX3
wild type, showing an unaltered amount of the demolybdo form of
MPT present in the purified proteins. The ratio of absorbance at
280 nm and 444 nm in the UV-Vis spectra of all variants were
identical in the range of 4.9 – 5.7, showing an almost 100%
saturation of the variants with FAD [24].
Analysis of the role of residues F1014 and P1015 in
mAOX3
The crystal structure of mAOX3 suggested that A807, Y885,
K889, F919 and F1014 are directly involved in substrate-binding
in mAOX3 [23]. An amino acid sequence alignment of mAOX3
with mAOX1, mAOX4, mAOX3I1 and bovine XOR showed
differences in conservation of residues in the active site among the
enzymes (Figure 1). The residues A807 and Y885 present in
mAOX3 are highly conserved in AOX1 enzymes and are replaced
by valine and a methionine in other isoforms, respectively
(Figure1). F919 is highly conserved between all vertebrate AOX
and XOR enzymes, while F1014 is only conserved in XOR
enzymes and varies among AOX homologues. To study the role of
F1014 of mAOX3, we exchanged it to an isoleucine (present in
mAOX1) and a valine (present in mAOX4) [18]. The adjacent
amino acid P1015 is also not conserved. To study its role, we
exchanged mAOX3-P1015 to a glycine (present in mAOX1) and
to an alanine (present in mAOX3l1). The catalytic constants of
mAOX3 wild type, mAOX3-F1014I, mAOX3-F1014V,
mAOX3-P1015A and mAOX3-P1015G are shown in Table 2.
All values were corrected for a molybdenum saturation of 100% of
each variant for a better comparability. In comparison to mAOX3
wild type, the variant mAOX3-F1014I showed a 7.4–33 fold
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decreased catalytic efficiency (kcat/KM) with benzaldehyde,
phthalazine and phenanthridine. Both, the substrate affinity and
rate of conversion were affected by the F1014I exchange.
mAOX3-F1014I was determined to be inactive with allopurinol
and N1-methylnicotinamide as substrates. Replacement of F1014
by valine resulted in a 2.1–11 fold decrease in catalytic efficiency
with all substrates. However, the KM values of the mAOX3-
F1014V variant were higher in comparison to wild type mAOX3.
In contrast, the kcat with benzaldehyde and phthalazine was
increased, while the kcat with N1-methylnicotinamide and
phenanthridine remained unchanged. Allopurinol was oxidized
with a 4.6 - fold lower kcat by mAOX3-F1014V in comparison to
mAOX3 wild type. The catalytic constants were also altered by
variation of P1015 to alanine or glycine. The catalytic efficiency of
mAOX3-P1015A and mAOX3-P1015G with benzaldehyde and
phthalazine was comparable to mAOX3 wild type. N1-methylni-
cotinamide was converted with a higher catalytic efficiency by
variants mAOX3-P1015A and mAOX3-P1015G in comparison
to mAOX3 wild type. The catalytic efficiency (kcat/KM) with
phenanthridine was higher for the variants mAOX3-P1015A and
mAOX3-P1015G in comparison to wild type mAOX3. The
increase in catalytic efficiency with allopurinol was comparable for
both mAOX3-P1015 variants.
In summary, exchange of F1014 to valine or isoleucine resulted
in a decrease in substrate affinity and catalytic efficiency with all
substrates tested. Thus, valine and isoleucine might interfere with
substrate binding due to steric interferences. The increase in KM is
consistent with the higher KM values determined for mAOX1
containing an isoleucine at this position with these substrates [25].
In contrast, the higher rate constants with benzaldehyde and
phthalazine obtained for mAOX1 were not observed with the
mAOX3-F1014I variant, however, exchange of mAOX3-P1015
by alanine or glycine resulted a higher kcat with bulky and charged
substrates. These changes might be based on two effects in the
mAOX3-P1015 variants. The smaller side chain of alanine and
glycine increases the flexibility of the peptide backbone and the
ability of Y885 to flip away from the substrate, as suggested
previously [23]. This might result in a better access of the substrate
to K889, thereby resulting in tighter binding and/or better
stabilization of the transition state. However, there is an up to 30-
fold difference in the catalytic efficiency with benzaldehyde
between mAOX1 (kcat/Km = 3.3460.56 min
21mM21), hAOX1
(kcat/Km = 0.9160.17 min
21mM21) and mAOX3 (kcat/Km
= 27.0366.37 min21mM21) [23,25,26]. While the mAOX3-
F1014I variant resembled the variation of catalytic efficiency
between mAOX1 and mAOX3, the up to 20-fold difference in the
rate constant between mAOX1, mAOX3 and hAOX1 was not
observed by a single variation of F1014 or P1015. Thus, more
Figure 1. Amino acid sequence alignment of selected parts of mAOX homologues and bovine XOR. Shown is an amino acid sequence
alignment of the region of amino acids 770-1030 of mAOX3 with the other AOX-isoform from mouse and bovine XOR (bXOR). Identical amino acid
residues are shaded in black, homologous amino acid residues are shaded in grey. For clarity, residues exchanged in mAOX3-‘‘active site1’’-K889H
variant are boxed in black. A grey box marks the position of mAOX3-F1014 and mAOX3-P1015 variants. The six residues exchanged in the mAOX3-
‘‘gating loop’’ variants are underlined. The alignment was created with CLC Sequence viewer Ver. 6.8.2.
doi:10.1371/journal.pone.0082285.g001
Figure 2. 8% native-PAGE of mAOX3 wild type and variants.
Lanes 1–12 contain 3–5 mg of purified protein, stained with Coomassie-
brilliant blue. 1, mAOX3 WT; 2, mAOX3-‘‘active site1’’; 3, mAOX3-‘‘active
site1’’-K889H; 4, mAOX3-‘‘active site1 + gating loop’’; 5, mAOX3-‘‘gating
loop’’; 6, mAOX3-FeSI-mAOX1; 7, mAOX3-FeSII-mAOX1; 8, mAOX3-FeSII-
FeSI-mAOX1; 9, mAOX3-P1015A; 10, mAOX3-P1015G; 11, mAOX3-
F1013I; 12, mAOX3-F1014V.
doi:10.1371/journal.pone.0082285.g002
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factors might contribute to the difference in the catalytic constants
of the AOX homologues.
The role of FeSI and FeSII on electron transfer and activity
of mAOX3
To analyze the effect of the two [2Fe2S] clusters for substrate
conversion in AOX enzymes, we generated three variants by
exchanging FeSI, FeSII and both FeSI/FeSII in mAOX3 by the
domains of mAOX1. The kinetic parameters (Table 3) of the iron-
sulfur domain variants were determined using molecular oxygen
(with the substrate phenanthridine) or DCPIP as terminal electron
acceptors in order to exclude mediator-based side effects. As
shown in Table 3, the exchanges of the iron-sulfur center domains
in mAOX3 to the ones present in mAOX1 did result in a decrease
in catalytic activity with all substrates tested. A decrease of reaction
rate was obtained for both electron acceptors, DCPIP (accepting
Table 1. Determination of the cofactor composition of the mAOX3 variants.
% Mo content1 % Fe content1 % MPT content2 A280/A444 A444/A550
mAOX3-WT 62613 5767 100610 5.2 3.3
mAOX3-F1014I 7069 65617 62624 5.2 3.1
mAOX3-F1014L 4568 49615 1006 5.2 3.2
mAOX3-P1015A 5569 75624 10562 5.7 3.1
mAOX3-P1015G 6064 6761 11662 5.4 3.2
mAOX3-FeSI-mAOX1 7964 6461 106610 5.6 3.4
mAOX3-FeSII-mAOX1 96612 73618 139637 5.6 3.1
mAOX3-FeSII-FeSI-mAOX1 101616 69610 128614 5.7 3.3
mAOX3-‘‘active site1’’ 4661 5260 9663 5.1 3.5
mAOX3-‘‘active site1’’-K889H 6363 6360 87611 4.9 3.3
mAOX3-‘‘active site1 + gating loop’’ 8566 5863 73622 5.4 3.2
mAOX3-‘‘gating loop’’ 6062 6661 7562 5.1 3.3
1Molybdenum (mM molybdenum/mM enzyme) and iron (mM 2 x [2Fe2S]/mM enzyme) contents were determined by ICP-OES (see Experimental procedures).
2Determined after conversion to the stable oxidized fluorescent product FormA. mAOX3-WT was set to 100%.
Relative molybdopterin (MPT) saturation, molybdenum and iron saturation and ratio of absorbance at 280 nm, 444 nm and 550 nm of mAOX3 variants in comparison
to reported values for the wild type enzyme.
doi:10.1371/journal.pone.0082285.t001
Table 2. Steady-state kinetic parameters of mAOX3 wildtype and mAOX3 variants containing single amino acid exchanges in the
active site.
substrate kinetic parameters3 mAOX3-WT4 mAOX3-F1014I mAOX3-F1014V mAOX3-P1015A mAOX3-P1015G
benzaldehyde1 kcat [min21] 68615 1963 128612 76614 9367
KM [mM] 2.560.2 22.762.7 21.563.2 2.260.1 3.360.2
kcat/KM [min21 mM21] 27.066.4 0.860.2 5.961.0 34.766.4 2862.7
phthalazine1 kcat [min21] 66615 5869 278614 179638 347664
KM [mM] 1.460.2 9.060.5 12.560.6 2.660.3 10.362
kcat/KM [min21 mM21] 47.3612.7 6.461.0 22.361.5 68.9616.6 33.769
phenanthridine2 kcat [min21] 85618 1163 85611 5816153 530649
KM [mM] 3261 73618 385670 99615 4762
kcat/KM [min21 mM21] 2.6360.58 0.1660.05 0.2260.05 5.8861.8 11.3761.19
N1-
methylnicotineamide1
kcat [min21] 2465 n.d. 2361 65611 11568
KM [mM] 12865.8 n.d. 482.3628 8763.4 88.762.3
kcat/KM [min21 mM21] 0.18560.4 - 0.04760.004 0.74360.132 1.29761.101
allopurinol1 kcat [min21] 73616 n.d. 1662 4669 3764
KM [mM] 1595673 n.d. 38606567 527663 426656
kcat/KM [min21 mM21] 0.045760.0103 - 0.004160.0008 0.087160.0203 0.086460.0145
1100 mM DCPIP was used as terminal electron receptor.
2Molecular oxygen in air saturated buffer was used as terminal electron acceptor.
3Determined in 50 mM Tris (HCl) pH 8.00 at 37uC; kcat was corrected for molybdenum content
4Values from [23] and corrected for molybdenum content.
n.d.: non detectable
doi:10.1371/journal.pone.0082285.t002
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electrons from Moco [27,28]) and O2 (reacting with the FAD site).
The effect on catalytic activity was less pronounced for the FeSI
variant, while the highest decrease in the catalytic activity was
observed for the variant containing both iron-sulfur domains of
mAOX1. Additionally, we determined the reduction potentials of
the cofactors present in the protein (Table 4). The reduction
potentials for the FAD/FADH2 redox pairs were found to be
similar in all variants. These values are close to the FADu/FADH2
reduction potential determined for rabbit AO (2212 mV) [12].
No detectable amount of FAD-semiquinone was observed during
the titration process. Exchange of the iron-sulfur domains had only
minor effects on the reduction potential of FeSII. By exchange of
FeSI or FeSI/FeSII to the ones found in mAOX1, a lower
reduction potential of FeSI was observed. The reduction potentials
of the MoIV/V and MoV/VI redox couples in mAOX3 wild type
were found to be similar for all three iron-sulfur domain mAOX3-
variants (Table 4). A linear correlation according to the Marcus
theory was only observed for the reduction potential difference
between the MoV/VI redox pair and FeSI, with values for the
electronic coupling matrix of HAB = 5.76610
21662.14610216
and reorganization energy of l = 2.57610466.846103 J/mol. A
previous report by Itoh et al. [29] examined the effect of Moco
domain swop between monkey and rat AOX on the conversion of
(S)-RS-8359. The authors observed that the substrate affinity and
susceptibility to substrate inhibition of the chimeric variants was
equal to the enzyme from which the Moco domain originated.
The rate constant of the chimeric variants on the other hand was
equal to the enzyme from which the iron-sulfur/FAD part
originated. It was concluded that the rate of conversion is
controlled by the iron-sulfur/FAD part, whereas the Moco
domain defines substrate affinity and susceptibility to substrate
inhibition. Our results show that substrate affinities of all iron-
sulfur domain variants were unchanged. Exchange of the FeSII
domain influenced the reduction potential of FeSI, but not the
reduction potentials of Moco or FAD. Thus, in consistence with
the results of the domain swapping of the rat enzyme, the rate of
substrate conversion is not determined by the redox potential of
the molybdenum atom. It is rather determined by structural effects
induced by the domain swapping of the FeS domains influencing
the electron transfer reaction by a change of the redox potential of
the FeS clusters.
Change of substrate specificity of mAOX3
The main amino acids involved in substrate binding in bXOR
were shown to be E802 (A807 in mAOX3) and R880 (Y885 in
mAOX3) [10,30]. The highly conserved residues F914 (F919 in
mAOX3) an F1009 in bXOR (F1014 in mAOX3) were shown to
provide additional van-der-Waals interactions to the substrate
[23,31]. In AOX enzymes a conserved lysine (K889 in mAOX3)
was proposed to be involved in substrate binding, which is a
histidine in XORs. As reported previously, the mAOX3-K889H
exchange decreased the catalytic activity 2–4 - fold, with lower KM
values for most substrates, which suggested a better access of
substrates to the active site due to the smaller side-chain [23]. We
generated the variant mAOX3-‘‘active site1’’ in which all residues
in the first coordination sphere around the substrate except K889
were exchanged to their counterparts in XOR (F776K/A807E/
D878L/L881S/Y885R/P1015T/Y1019L). The resulting variant
mAOX3-‘‘active site1’’ was devoid of activity towards most
substrates tested. Only allopurinol was oxidized at a very low
but significant rate of 1461 min21 (Table 5). However, additional
introduction of the exchange of K889 to histidine in this variant
recovered the activity with benzaldehyde, and phthalazine and,
additionally, was able to convert hypoxanthine with a kcat of
2561 min21. Benzaldehyde and phthalazine were oxidized with
higher rate constants in comparison to mAOX3 wild type,
however, the KM values were largely increased. Thus, the
additional introduction of K889H converted mAOX3 to a
‘‘XOR-type’’ enzyme (Figure 3). In order to test the additional
effects of amino acids building a hydrogen-bond network in the
second coordination sphere, we tested the ‘‘gating loop’’ variant
(K889H/S1011G/V1012I/G1013S/K1016V/Y1020N) on sub-
strate binding, in addition to variant mAOX3-‘‘active site1 +
gating loop’’, which contains amino acid exchanges in the first and
second coordination sphere (F776K/A807E/D878L/L881S/
Y885R/K889H/S1011G/V1012I/G1013S/P1015T/K1016V/
Table 3. Steady-state kinetic parameters of mAOX3 wild type and mAOX3 variants containing the FeS-domains of mAOX1.




21] 68615 4863 3865 2364
KM [mM] 2.560.2 3.660.3 1.660.1 2.260.1
kcat/KM [min
21 mM21] 2766.4 13.461.5 23.761.9 10.361.9
phthalazine1 kcat [min
21] 66615 4563 3265 3065
KM [mM] 1.460.2 1.260.1 1.460.2 1.060.1
kcat/KM [min
21 mM21] 47.3612.7 38.363.9 22.964.8 29.165.3
phenanthridine2 kcat [min
21] 85618 4363 2664 2564
KM [mM] 3261 3562 3065 2862
kcat/KM [min
21 mM21] 2.6360.58 1.2360.1 0.8860.21 0.8760.17
allopurinol1 kcat [min
21] 73616 2562 2064 1062
KM [mM] 1595673 1338643 8996145 10266108
kcat/KM [min
21 mM21] 0.045760.0103 0.018560.0013 0.02260.0055 0.0160.0022
1100 mM DCPIP was used as terminal electron receptor.
2Molecular oxygen in air saturated buffer was used as terminal electron acceptor.
3Determined in 50 mM Tris HCl pH 8.00 at 37uC; kcat was corrected for molybdenum content
4Values from [23] and corrected for molybdenum content.
doi:10.1371/journal.pone.0082285.t003
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Y1019L/Y1020N). The affinity of mAOX3-‘‘active site1 + gating
loop’’ towards allopurinol, benzaldehyde and phthalazine was
increased 3.7–22 fold in comparison to the variant mAOX3-
‘‘active site1’’-K889H. On the other hand, the catalytic activity
decreased 2–12 fold for these substrates. The catalytic efficiency of
the mAOX3-‘‘active site1 + gating loop’’ towards hypoxanthine
was determined with values 5 times higher in comparison to
mAOX3 wild type, but 2 times lower to that of the mAOX3-
‘‘active site1’’-K889H variant. For comparison, a mAOX3 variant
containing only the ‘‘gating loop’’ showed no detectable activity
towards allopurinol, hypoxanthine and xanthine and only residual
activity (1.3% in comparison to mAOX3 wild type) with
benzaldehyde and phthalazine as substrates, showing that the
additional amino acid exchanges are required to obtain a
considerable activity. Thus, introduction of the ‘‘gating loop’’
exchange increased the substrate affinity in comparison to
mAOX3-‘‘active site1’’-K889H, but resulted in a decrease in
substrate conversion of the enzyme.
Molecular Docking
To interpret the results of the kinetic analyzes, we performed
molecular docking analyzes. We have first docked hypoxanthine
and benzaldehyde into the active sites of the wild type and
mAOX3 variants by using the molecular docking software
AutoDock (Fig. 4 A and B). The most favorable complexes were
then regarded as the initial geometries for the following MD
simulations. The computational results showed that in the
mAOX3 wild type, the position of the molybdenum coordination
is partially stabilized by two important hydrogen bonds that are
established with Q772 and E1266. Q772 established one hydrogen
bond with the axial oxygen that is bound to the molybdenum ion
(on average 2.50 A˚) and E1266 interacts very closely with the
hydroxyl group of the metal complex through a short hydrogen
bond (on average 2.00 A˚). S1085 and K889 stabilize the anionic
nature of E1266. S1085 interacts with E1266 by a short hydrogen
bond (on average 2.50 A˚) while the K889 forms an ionic bridge
with it (on average 3.50 A˚).
The computational results for the docking of hypoxanthine to
mAOX3 wild type (Fig. 4A) showed a binding of the imidazole
ring pointing towards the hydroxyl group of the molybdenum
atom (2.0460.20 A˚). The position of hypoxanthine in the active
site is stabilized by D878 trough a hydrogen bond involving the
carbonyl group and by F919 via p-stacking interactions (,3.35 A˚).
The modeled position of benzaldehyde in the active site is similar
to the binding position of hypoxanthine (Fig. 4B). The aldehyde
group resides close to the hydroxyl group of the Mo-OH group
(3.4660.18 A˚) and is positioned correctly in order to be oxidized
to the corresponding carboxylic acid. The conformation adopted
by benzaldehyde is also guided by the p-stacking interactions with
F919 (,3.50 A˚) and especially by K889, which establishes a
hydrogen bond (3.1360.60 A˚).
The computational results for the mAOX3-‘‘active site1’’
variant showed that the metal cluster is deviated from the position
that it occupies in the wild type enzyme. This occurs due to the
disruption of key hydrogen bonds between the metal complex and
E1266 or Q772. This fact is supported by a movement E1266 that
no longer interacts with the hydroxyl group of the metal complex.
The new conformation adopted by E1266 is endorsed by the ionic
bridge provided by the Y885R variation (2.50 A˚), but also by the
close proximity of K889. We believe that the proximity of R885
and K889 in the active site creates a strong positively charged
space that attracts the negatively charged E1266. All of these
factors together might result in an inactive enzyme.
The binding of hypoxanthine in the mAOX3-‘‘active site1’’
variant is very different from the wild type enzyme (Figure 4C).
The molecule has now flipped by 180u in the active site and the
imidazole ring no longer interacts with the metal cluster. The
D878L variation additionally precludes any interaction of the
substrate with this part of the active site. In the wild type, the
aspartate is responsible for making a hydrogen bond with the
carbonyl group of hypoxanthine. The binding position of
benzaldehyde in the mAOX3-‘‘active site1’’ variant is also
different from what is observed in the wild type enzyme
(Figure 4D). However, in this case, the aldehyde group remained
aligned with the hydroxyl group of the metal complex. The
computational results suggest that the loss of activity might be
related to the absence of the key interactions between the hydroxyl
group and E1266.
The additional introduction of the K889H exchange to the
mAOX3-‘‘active site1’’ variant resulted in an activity towards
benzaldehyde and hypoxanthine. The studies showed that the
overall rearrangement of the residues of the active site in the
mAOX3-‘‘active site1’’-K889H variant closely resembled that of
the wild type enzyme. The metal complex continues to be firmly
aligned in the active site with the hydroxyl group pointing towards
the entrance of the active site tunnel provided by E1266 and
Q772. The main differences between the mAOX3-‘‘active site1’’-
K889H variant and the wild type enzymes are at the top and
bottom regions of the active site where the substrate binds. The
variation of D878 to a leucine turns the top region of the active site
almost hydrophobic, similarly to what is found in the mAOX3-
‘‘active site1’’ variant. Consequently, any interaction between the
substrate and this region is precluded. At the bottom of the active
site, the variations of Y885 to an arginine and K889 to a histidine,
did not lead to any significant rearrangement of the active site,
except to the closer ionic interaction between E1266 and R885.
Interestingly, in this case the interaction between E1266 and the
hydroxyl group of the metallic center is not destroyed. Here,
K889H removes the high concentration of positive charge in a
specific region of the active site. The binding poses of hypoxan-
thine in the variant and wild type enzymes are very similar
(Fig. 4E). The imidazole ring remained close to the hydroxyl group
of the metallic center (3.766039 A˚) but the molecule has flipped
180u. Thus, the carbonyl group no longer interacts with the top
part of the active site, and establishes a hydrogen bond with R885
Table 4. Reduction potentials of mAOX3 and selected
variants determined by electron paramagnetic resonance
spectroscopy and UV/Vis titrations.
Mo IV/V Mo V/VI FeSI FeSII
FAD/
FADH2
mAOX3-WT 2468611 229469 2206610 2286612 2185611
mAOX3-FeSI-
mAOX1
244065 2234633 2198614 2230621 2180611
mAOX3-FeSII-
mAOX1
2441638 2290643 2273622 2260623 2201611
mAOX3-FeSII-
FeSI-mAOX1
2422628 231329 2305613 2261622 2174612
Proteins were titrated anaerobically with sodium dithionite at room
temperature in the presence of mediators as enlisted in experimental
procedures. Signal intensities were determined by weighted fit of simulated
spectra to experimental data. Weight parameters plotted against electrode
potential were fitted to the Nernst-equation as described in experimental
procedures. Reduction potentials of FeSI are lower in mAOX3 variants
exhibiting iron sulfur domains from mAOX1.
doi:10.1371/journal.pone.0082285.t004
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(1.9860.22 A˚). This shows that the important role of D878 in the
wild type enzyme was replaced by R885 in the variant enzyme.
Interestingly, in the wild type enzyme K889 occupies a similar
position that is occupied by R885 in the mAOX3-‘‘active site1’’-
K889H and bXOR. However in that case, the interaction
between hypoxanthine and D878 is preferred instead. The
binding poses of the benzaldehyde in the wild type and the
mAOX3-‘‘active site1’’-K889H variant are also very similar
(Fig. 4F). The aldehyde group is in close contact to the hydroxyl
group of the metal complex. The changes in the orientations of the
substrate are not observed here, since benzaldehyde does not
interact with D878. However, in the mAOX3-‘‘active site1’’-
K889H variant the presence of R885 allows the carbonyl group of
the aldehyde to establish a hydrogen bond with this residue. Thus,
this variation might improve the substrate recognition and turn the
active site more prone for this type of substrates. This explains the
improved activity of mAOX3-‘‘active site1’’-K889H with benzal-
dehyde.
Conclusions
AOX isoforms share a high amino acid sequence identity,
however, their substrates specificities differ. Our results show that
single variations of F1014 and P1015 in mAOX3 to residues found
in mouse AOX homologues cannot explain the differences in the
kinetic parameters to their full extent. Thus, more amino acid
residues or synergistic effects determine the specificities and
differences in the active site of these enzymes.
This work also shows that exchange of iron-sulfur domains
influence the rate constant but not the substrate affinity of
mAOX3. This is in accordance with Moco-domain swop
experiments performed with monkey and rat AOX orthologs
[29]. A correlation of kcat and the difference in reduction potential
between the Mo V/VI pair and FeSI was observed. However, our
data do not allow favouring changes in the electron transfer or
structural changes induced by the domain swop as a cause for the
altered rate constants. Given the interaction at the interface of
mAOX3 subdomains it seems impossible to alter the electron
transfer without inducing structural changes.
Additionally, XOR and AOX enzymes act on different, yet
overlapping sets of substrates, and XOR enzymes usually show
higher rate constants towards their specific substrates. Here, we
present for the first time the successful conversion of an AOX
enzyme to an XOR enzyme that can convert hypoxanthine as
substrate. This change in substrate specificity was obtained by
exchange of several amino acids in the substrate binding site. The
results show the importance of K889 in retaining the interaction
between E1266 and the hydroxyl group of the molybdenum atom
(see Table 6 for a more detailed analysis). Thus, the inactivity of
the AOX3-‘‘active site1’’ variant is caused mainly by the
disruption of a key hydrogen bond between E1266 and the
hydroxyl group of the molybdenum site, a reaction essential to
start the base-catalyzed mechanism. By additional introduction of
the K889H exchange, the hydrogen bond network remained
established. Thus, the results show that the conversion of the AOX
to a XOR enzyme observed for the mAOX3-‘‘active site1’’-
K889H variant is only possible because the interaction between
E1266 and the hydroxyl group of the metal complex is not
disrupted. In the case of hypoxanthine it is also important to
emphasize that the absence of D878 is compensated by the
mutation of Y885 by an arginine. This allows hypoxanthine to
reside in a specific orientation in the active site with the imidazole
ring pointing towards the metal complex ready for catalysis.
Materials and Methods
Protein Purification and site directed mutagenesis
For site-directed mutagenesis of the presented mAOX3
variants, the expression vector pMMA1 [24] was used as a
template. Base pair exchanges were introduced into pMMA1 by
PCR mutagenesis. The mAOX3 gene containing base pair
exchanges substituting F1014I, F1014V, P1015A and P1015G
were cloned into the Pfl23II-SalI sites of pMMA1. Exchange of
Table 5. Steady-state kinetic parameters for mAOX3 wild type and mAOX3 variants containing numerous amino acids present in
the active site of bovine XOR.










benzaldehyde kcat [min21] 68615 n.d. 234615 5365 0.960.2
KM [mM] 2.560.2 n.d. 2122688 571636 4.563.4
kcat/KM [min21 mM21] 2766.4 - 0.11060.008 0.09260.011 0.19960.151
phthalazine kcat [min21] 66615 n.d. 524633 4267 (359635)4 0.960.1
KM [mM] 1.460.2 n.d. 733652 33618 (2680662214)4 0.960.5
kcat/KM [min21 mM21] 47.3612.7 - 0.71560.068 1.28760.744
(0.01360.002)4
0.99760.559
hypoxanthine kcat [min21] 2.160.4 n.d. 2561 560 n.d.
KM [mM] 36856854 n.d. 40856227 17366155 n.d.
kcat/KM [min21 mM21] 0.0005760.00018 - 0.0062460.00048 0.0028760.00035 -
allopurinol kcat [min21] 73616 1461 9566 3963 n.d.
KM [mM] 1595673 29336380 133610 620616 n.d.
kcat/KM [min21 mM21] 0.045760.0103 0.00560.001 0.71860.067 0.06360.005 -
1Determined in the presence of 100 mM DCPIP in 50 mM Tris (HCl) pH 8.00 at 37uC; kcat was corrected for molybdenum content
2Values from [23] and corrected for molybdenum content.
n.d. none detectable.
4phthalazine:DCPIP reaction was biphasic.
doi:10.1371/journal.pone.0082285.t005
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iron-sulfur domains was achieved by PCR-based fusion of the
corresponding mAOX1 sequence derived from pSL205 [25] to the
appropriate sequence from mAOX3 allowing cloning into the NdeI
sites of pMMA1. Sequences coding for mAOX3-‘‘active site1’’
variant (F776K/A807E/D878L/L881S/Y885R/P1015T/Y1019L)
and the mAOX3-‘‘gating loop’’ variant K889H/S1011G/V1012I/
G1013S/K1016V/Y1020N) were cloned into the Pfl23II-SpeI sites of
pMMA1. The variant mAOX3-‘‘active site1’’-K889H was created
by PCR mutagenesis and cloned into the Pfl23II-SpeI sites of
pMMA1. All constructs express the mAOX3 variants as N-terminal
fusion proteins with a His6-tag. The mAOX3 wild type and variants
were expressed and purified as reported previously [24]. The proteins
were stored in 100 mM potassium phosphate pH 7.4 at280uC until
usage, without loss of activity. The molybdenum and iron contents
were determined by ICP-OES as described previously [24]. The
Moco content was quantified after conversion to its fluorescent
oxidation product Form A as described in [32].
Enzyme Assays
Steady state kinetics were performed at 37uC in 50 mM Tris-
HCl (pH 8.0) and 1 mM EDTA with variable substrate concen-
trations (0–250 mM benzaldehyde for mAOX3 wild type, 0–5 mM
benzaldehyde for mAOX3 variants, 0–5 mM N1-methylnicoti-
neamide, 0– 400 mM phenanthridine, 0–8 mM hypoxanthine
solved in 0.1 M NaOH for mAOX3 wild type, 0–5 mM
hypoxanthine solved in 0.1 M NaOH for mAOX3 variants, 0–
150 mM hypoxanthine solved in 0.1 M NaOH for bXOR and 0–
5 mM allopurinol solved in 0.1 M NaOH) and protein concen-
trations in a range of 50–200 nM. As electron acceptor, 100 mM
2,6-dichlorophenolindophenol (DCPIP for mAOX3 variants) or
molecular oxygen in air-saturated buffer (for phenanthridine) were
used in a final reaction volume of 500 ml. Enzyme activity was
monitored for 60 seconds at 600 nm for DCPIP and 321 nm for
phenanthidine. Specific activity was calculated using the molecular
Figure 3. Active site structure of mAOX3. A, Stick representation of E1266 and residues exchanged in mAOX3-‘‘active site1’’-K889H in the crystal
structure of mAOX3 WT (pdb:3ZYV). B, Stick representation of residues of desulfurated bXO (pdb:3EUB) corresponding to the amino acids in Panel A.
C, Stick representation of residues in mAOX3 corresponding to the residues shown in Panel D. Y885 builds hydrogen-bonds to the backbone of
G1013 and K889, indicated by yellow dotted lines D, Stick representation of residues involved in a hydrogen network at the entrance to the active site
of bXOR. The hydrogen-bonding network is established by R880, G1006, I1007, S1008 and N1015 in bXOR represented by yellow dotted lines.
Through the interactions, the position and orientation of T1010 is altered in comparison to K1016 of mAOX3 in panel C. Figures were created using
MacPymol [56]Ver. 0.99rc6.
doi:10.1371/journal.pone.0082285.g003
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extinction coefficient of 21,400 M21cm21 for mAOX3,
4775 M21cm21 for phenanthridine, and 16,100 M21cm21 for
DCPIP [33]. Kinetic parameters were obtained by nonlinear
fitting to the Michaelis-Menten model using R, build 2.12.00 [34].
Mean values with standard deviation were obtained from at least 3
independent measurements. kcat was normalized to a 100%
molybdenum content.
EPR-Redox Titration
Anaerobic redox titrations were performed at ambient temper-
ature (2462uC) under constant mixing under 5% H2/95% N2
atmosphere (COYlab USA). The potentials were monitored with a
platinum combination electrode with Ag/AgCl reference (Pt 5900
A, Schott Instruments, Germany) fitted to an inolab 7310 pH-
meter (WTW Germany) calibrated with a saturated quinhydrone
solution at pH 7 and 9. Reaction mixture contained 20 mM –
50 mM of protein, 5 mM of mediator and 100 mM potassium
phosphate pH 7.4 in a total volume of 2 mL. The mediators used
were 2,6-dichloroindophenol (217 mV), phenazinemethosulfate
(80 mV), 1,4-naphtochinone (60 mV), toluideneblue (31 mV),
methyleneblue (11 mV), indigocarmine (2125 mV), anthrachi-
none-2-sulfonate (2225 mV), phenosafranine (2252 mV), safra-
nine T (2289 mV) and deiquat (2350 mV). The potential was
titrated by stepwise addition of 5 mM–15 mM sodium dithionite
(Na2S2O4) dissolved in 100 mM potassium phosphate pH 7.4.
After stabilization of the potential (usually after 2 min), 80 mL of
sample were withdrawn with a Hamilton syringe, transferred to a
4 mm EPR tube and frozen immediately in liquid nitrogen.
9.5 GHz X-band cw-EPR spectroscopy was carried out on a
home-assembled spectrometer consisting of an ER041 MR
microwave bridge, a Stanford research lockin amplifier SR810,
an AEG magnet with Bruker ER081S power supply and a Bruker
SHQ resonator. EPR spectra were recorded at 10 K (for FeSII
and FeSI) and 120 K (for Moco) using an Oxford ESR 910 helium
flow cryostat controlled by an Oxford ITC502 temperature
controller. The microwave frequency was measured with an
Agilent 53181A frequency counter. For determination of g-values
the magnetic field was calibrated with an external g-standard
(LiLiF, g = 2.002293) [35]. Spectra were simulated using the
EasySpin Toolbox (Build 4.5.0) and weights fitted to experimental
data using Matlab’s (R2012) trust-region-reflective non-negative
least square algorithm. Weight parameters plotted against the
potential were fitted with n = 1 to Nernst equation by non-linear
regression using R build 2.12.0 [34].
UV-VIS-Redox Titrations
Anaerobic redox titrations were performed at 2261uC (Agilent
89090A #100 peltier) under 5% H2/95% N2 atmosphere
(COYlab, USA). Mixing with 600 rpm was applied for 30 seconds
after the addition of dithionite. The potentials were monitored
with a platinum combination electrode with Ag/AgCl reference
(Pt 5900 A, Schott Instruments, Germany) fitted to an Inolab 7310
pH-meter (WTW Germany) calibrated against saturated quinhy-
drone solution at pH 7 and 9. Reaction mixtures contained
3 mM–5 mM of protein in 100 mM potassium phosphate pH 7.4
in a total volume of 3 mL. The potential was titrated with stepwise
addition of 1 mM–2 mM sodium dithionite (Na2S2O4) solved in
100 mM potassium phosphate pH 7.4. After stabilization of the
potential (usually after 2 min), triplicate spectra were recorded on
an Agilent 8453 and corrected for the absorbance in the range of
785–800 nm. Absorbance at 444 nm (for FAD) and 550 (for
combined [2Fe-2S] centers) plotted against the potential was fitted
with n = 2 to Nernst equation by non-linear regression using R
build 2.12.0 [34].
Molecular Docking
All the compounds were studied using the molecular docking
software AutoDock [36] and the vsLab plug-in [37]. The structure
of the receptor was built from the PDB structure of mouse AOX3
(pdb code 3ZYV at 2.9 A˚ of resolution). The ligands were built
with GaussView [38] and they were protonated at physiological
pH. In the docking process we used the Lamarckian genetic
algorithm (LGA). The number of generations, energy evaluations,
and docking runs were set to 370,000, 1,500,000, and 50,
respectively. The types of atomic charges were taken as Kollman-
all-atom for the receptor and Gasteiger for the compounds. The
final solutions were retrieved from the molecular docking process
according to the criteria of interacting energy.
Molecular Modelling
Since the crystallographic structure of mAOX3 has some gaps
in its 3D sequence, the construction of these missing loops was
carried out with program Modeller9 version 11 [39–42]. The
missing parameters of the entire Moco cofactor (molybdenum
Table 6. Interactions established by MD simulation within the metallic active center in the wild type and variant enzymes.
E1266-OH E1266-S1085 Q772-O D878-Sub E1266-K889/R885* R885-Sub







































*only available in the respective mutated enzymes.
a) substrate is hypoxanthine
b) substrate is benzaldehyde
doi:10.1371/journal.pone.0082285.t006
Figure 4. Molecular docking and molecular dynamic studies. A, Wild type enzyme with hypoxanthine. B, Wild type enzyme with
benzaldehyde bound in the active site. C, mAOX3-‘‘active site1’’ variant with hypoxanthine. D, mAOX3-‘‘active site1’’ variant with benzaldehyde
bound in the active site. E, mAOX3-‘‘active site1’’-K889H with hypoxanthine. F, mAOX3-‘‘active site1’’-K889H with benzaldehyde bound in the active
site. Hydrogen bonds are marked with a dashed line and the altered residues are highlighted in red.
doi:10.1371/journal.pone.0082285.g004
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penta-coordinated to molybdopterin, sulfido, oxo, and hydroxo
ligands) were determined. The Moco model structure was
optimized using DFT, with the exchange correlation functional
B3LYP [43–45] and basis set 6-31G+(d) for all atoms except
molybdenum, for which the LanL2DZ pseudopotential was
employed. A semiflexible model approach was used to calculate
the force constants for the bond and angles parameters of the
molybdenum metallocenter [46]. Electrostatic charges were
determined from a RESP fitting of Merz2Kollman charges
[47]. Dihedral force constants involving the Mo were set to zero,
while transferable van der Waals atomic parameters were taken
from the literature [48]. The parameters for the Fe2S2 centers
were taken from literature too [49].
Molecular Dynamics Simulation
The structures of the six different complexes (wild type




from the previous docking protocol. For the parameterization of
benzaldehyde and hypoxanthine the following protocol was used.
The geometries of the molecules were built with GaussView
software [38]. The optimized geometries and electronic properties
were calculated with Gaussian09 software [50]. The restricted
Hartree-Fock (RHF), with the 6-31G(d) basis set was used in all
calculations. Atomic charges were recalculated using the RESP
algorithm [47]. This methodology was chosen for its consistency
with that adopted for the parameterization approach in AMBER
10.0 simulation package [51]. The geometry optimizations and a
Molecular Dynamics (MD) simulation on the six complexes were
performed with the parameterization adopted in AMBER 10.0,
using the parm99SB force field for the protein and cofactors, and
the generalized amber force field (GAFF) for the ligands [52].
All hydrogen atoms were added with the Amber software X-
Leap [51], taking into account all residues in their physiological
protonation state. The only exception was the D878, which was
protonated. Twenty counter-ions (Na+) were employed to
neutralize the high negative charges of the system. The X-Leap
program was also used for this purpose. In these simulations, an
explicit solvation model with pre-equilibrated TIP3P water
molecules was used, filling a truncated octahedral box with a
minimum distance of 12 A˚ between the box faces and any atom of
each complex. The average size of each system was 172,000
atoms. The complex geometries were minimized in two stages:
first the protein, cofactor and substrate were kept fixed and only
the position of the water molecules was minimized. Afterwards the
full system was minimized. Subsequently, an MD simulation of
100 ps at constant volume and temperature, and considering
periodic boundaries conditions was run, followed by 2 ns of MD
simulation with the NPT ensemble, in which Langevin dynamics
was used (collision frequency of 1.0 ps21) to control the
temperature at 303.15 K [53]. These simulations were carried
out using the Sander module. Bond lengths involving hydrogen
atoms were constrained using the SHAKE algorithm, and the
equations of motion were integrated with a 2 fs time step using the
Verlet leapfrog algorithm [54]. The Particle-Mesh Ewald (PME)
method [55] was used to include the long-range interactions, and
the nonbonded interactions were truncated with a 10 A˚ cut-off.
The MD trajectory was saved every 2 ps and the MD results were
analysed with the PTRAJ module of AMBER 10.0 [51].
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